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Abstract
Background: Factors responsible for invasive and metastatic progression of prostate cancer (PCa) remain largely
unknown. Previously, we reported cloning of prosaposin (PSAP) and its genomic amplification and/or
overexpression in several androgen-independent metastatic PCa cell lines and lymph node metastases. PSAP is the
lysosomal precursor of saposins, which serve as activators for lysosomal hydrolases involved in the degradation of
ceramide (Cer) and other sphingolipids.
Results: Our current data show that, in metastatic PCa cells, stable down-modulation of PSAP by RNA-interference
via a lysosomal proteolysis-dependent pathway decreased b1A-integrin expression, its cell-surface clustering, and
adhesion to basement membrane proteins; led to disassembly of focal adhesion complex; and decreased
phosphorylative activity of focal adhesion kinase and its downstream adaptor molecule, paxillin. Cathepsin D
(CathD) expression and proteolytic activity, migration, and invasion were also significantly decreased in PSAP
knock-down cells. Transient-transfection studies with b1A integrin- or CathD-siRNA oligos confirmed the cause and
effect relationship between PSAP and CathD or PSAP and Cer-b1A integrin, regulating PCa cell migration and
invasion.
Conclusion: Our findings suggest that by a coordinated regulation of Cer levels, CathD and b1A-integrin
expression, and attenuation of “inside-out” integrin-signaling pathway, PSAP is involved in PCa invasion and
therefore might be used as a molecular target for PCa therapy.
Background
Prosaposin (PSAP) is a dual-function highly conserved
glycoprotein that exists as the lysosomal precursor of
four small sphingolipid activator proteins, known as
saposins A, B, C and D [1-3]. Saposins are generated by
proteolytic cleavage of another lysosomal protease,
cathepsin D (CathD) [4-6]. In lysosomes, mature sapo-
sins are intensively involved in metabolism of sphingoli-
pids and ceramide (Cer), functioning either as essential
co-factors for sphingolipid hydrolases and/or destabiliz-
ing the complex of lipids and membranes [3]. PSAP also
exists as a secreted protein, which has been found in
various body fluids such as milk, serum, and seminal
fluid [2]. Secreted PSAP is a well-known potent neuro-
trophic factor [7,8]. Total PSAP deficiency is lethal in
both man and mice [2]. However, deficiency of indivi-
dual saposin proteins is responsible for a number of
lipid storage diseases [9-11].
Homozygous inactivation of PSAP gene in mice led to
shrinkage and atrophic changes in the male reproductive
organs, with gross pathological features including a
reduction in size and weight of the testes, seminal vesi-
cle, and prostate gland [12]. Histological examination of
the involuted prostate tissue revealed the presence of
undifferentiated epithelial cells. Collectively, these data
support a developmental role for PSAP in prostate
gland. During our search for a prostate tumor marker,
we cloned PSAP as a secreted protein from the highly
invasive and metastatic PCa cell line PC-3 [13]. In addi-
tion, we discovered its overexpression and/or genomic
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or metastatic PCa cell lines and in punch biopsy sam-
ples of LuCaP PCa xenograft and lymph node metas-
tases. Interestingly, PSAP expression in C4-2B, an AI-
bone metastatic PCa cell line was significantly higher
than in its parental isogenic and marginally tumorigenic
cell line, LNCaP [13]. Recently, we demonstrated that
saposin C and TX14A-synthetic peptide, two well-
known bioactive derivatives of PSAP, act as cell survival
and anti-apoptotic factors, stimulate migration and inva-
sion, and activate PI3K/Akt- and MAPK-signaling path-
ways in PCa cell lines [14-16]. However, the underlying
mechanisms of PSAP regulation of PCa cell migration
and invasion have not been investigated.
In this study, we evaluated the contribution of PSAP
in multistep process of invasion by using an RNA-inter-
ference strategy and transient or stable transfectants of
metastatic PCa cell lines. Down-modulation of PSAP
expression did not alter PCa cell growth. However, by
increasing cellular Cer levels and decreasing b1A-integrin
and CathD expression, PSAP significantly decreased the
cell adhesion, migration, and invasion abilities of AI-
PCa cells. Taken together, our data support a role for
PSAP in invasive and metastatic progression of PCa.
Results
PSAP is overexpressed in metastatic PCa cells
As shown in Fig. 1A, PSAP and saposin C are expressed
at higher levels in metastatic PCa cell lines than in the
normal prostate epithelial cells (Pr.Ep). In addition,
using other PCa progression models of isogenic cell
lines, we observed consistent data for increased PSAP
expression level from normal, poorly tumorigenic, or
non-tumorigenic cells to androgen-independent and/or
highly invasive and metastatic cell lines such as LNCaP/
C4-2B, PC-3/PC-3M, and p69-M12-M2182 (see addi-
tional file 1). The biological significances of PSAP as an
intracellular or extracellular soluble protein in PCa cells
are largely unknown. Our attempts to increase the
expression of PSAP in PC-3 and DU-145 cells beyond
their endogenous level failed. Therefore, we decided to
use RNA interference strategy to specifically down-mod-
ulate PSAP expression. After establishing several control
or PSAP-KD clones, we randomly selected two clones
for each category for further analysis. As shown in Fig.
1B, stable transfection of the two metastatic PCa cell
lines with a PSAP-shRNA vector decreased the PSAP
mRNA level. In addition, both the intracellular and
extracellular PSAP and saposin C protein levels in the
two PSAP-KD clones (P5 and P16 in PC-3 and P15 and
P 3 2i nD U - 1 4 5c e l ll i n e )w e r esignificantly reduced by
≥70% as compared with two control clones (C1 and C3
in PC-3 and C9 and C13 in DU-145 cell line). Using
direct cell counting with haemocytometer and MTS cell
proliferation assay, we did not find a significant reduc-
tion (≤ 5%) in the PSAP-KD cells growth (data not
shown). In addition, we also tested the effect of PSAP
down-modulation in soft agar colony formation assay.
This study also did not show any significant changes in
the size or number of colonies in PSAP-KD clones com-
pared to control transfectants. To evaluate the biological
activities of PSAP, we generated a mammalian expres-
sion vector expressing the biologically active full-length
rhPSAP (see additional files 2, 3, 4, 5). Treatment of
both the control and PSAP-KD clones with rhPSAP at
0.1 to 10 nM did not stimulate their growth rate (data
not shown). Overall, these results suggest that altera-
tions in the intracellular or extracellular PSAP levels do
not affect the anchorage-dependent and -independent
growth of PC-3 and DU-145 cells.
PSAP down-modulation decreases PCa cells adhesion,
migration, and invasion
During routine cell culture and trypsinization, we
noticed that in both cell lines, the PSAP-KD clones
were detached more easily than their control clones or
parental cell types. Therefore, we investigated cell adhe-
sion to the major components of the basement mem-
brane such as laminin (LN) and fibronectin (FN). We
found that PSAP-KD clones showed a significant reduc-
tion of cell adhesion on FN- or LN-coated plates as
compared with the control clones (Fig. 1C). In the PC-3
cell line, compared to control transfectants, the adhesion
of the PSAP-KD clones on FN and LN was reduced by
78% and 71%, respectively. Likewise, the adhesion of the
PSAP-KD clones in the DU-145 cells was decreased by
49% on FN and 69% on LN. We obtained a comparable
decrease in cell adhesion for the other extracellular
matrix (ECM) proteins such as collagen I or IV in the
PSAP-KD clones (data not shown). It is noteworthy that
the decreased ability of cell adhesion to ECM proteins
was associated with clear morphological changes in
PSAP-KD clones as compared with their control coun-
terparts. Control transfectants demonstrated morpholo-
gical indications of adhesion phenotype such as
spreading, membrane protrusion and ruffles, and polar-
ity on all ECM proteins examined. In contrast, PSAP-
KD cells appear lower in number and condensed with
smaller and either delayed or multi-polar membrane
protrusion (Fig. 1D).
Defective adhesion might reflect itself in migration
and invasion as the two important malignancy-asso-
ciated phenotypes. Our previous studies revealed that
active molecular derivatives of PSAP (i.e. saposin C or
TX14A peptide) stimulate PCa cell motility and invasion
[14,16]. Next, we examined the effect of PSAP down-
modulation on these phenotypes by using the conven-
tional Boyden Chamber (transwell filter) assays. We
found that the PSAP-KD clones showed a significant
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Page 2 of 18Figure 1 PSAP gene silencing decreases metastatic PCa cell adhesion to basement membrane proteins. (A) PSAP over-expression in
metastatic prostate cancer cell lines. Equal amount of cell lysates or supernatants from PC-3, DU-145, and normal prostate epithelial (Pr.Ep) cells
were subjected to western blotting with anti-PSAP and saposin C antibodies. (B) Stable PSAP down-modulation was accomplished by short-
hairpin RNA targeted at PSAP gene. PC-3 and DU-145 metastatic PCa cell lines were stably transfected with a G418-resistant vector containing a
shRNA sequence specific for human PSAP or a scrambled control sequence. Total RNA was extracted for RT-PCR (top). GAPDH transcript was
used as an internal control for RNA loading. Cell lysates and culture supernatants were subjected to immunoblotting with PSAP antibody.
GAPDH antibody was used for protein loading. (C and D) PC-3 and DU-145 cell adhesion to ECM proteins was examined by seeding 1.5 × 10
4
cells per well in 96-well plates pre-coated with 10 μg/ml fibronectin (FN) or laminin (LN). After 2 h incubation, adhered cells were fixed and
stained with toluidine blue. Cells were photographed and counted from ten random fields at 100 × magnification. Columns, mean of three
independent samples run together; bars, ± SEM, p < 0.0001, ANOVA was used to compare PSAP-KD and control clones. Each experiment was
repeated three times independently. C1 and C3 in PC-3 and C9 and C13 in DU-145 were control clones (shRNA-scrambled vector) and P5 and
P16 in PC-3 and P15 and P32 in DU-145 were PSAP-KD clones (shRNA-PSAP).
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Page 3 of 18decrease of migration by 70% in PC-3 and 79% in DU-
145 compared to the control clones (Fig. 2A &2B). In
addition, PSAP down-modulation further reduced the
ability of cell invasion through the Matrigel-coated
membrane by 78% in PC-3 cells and by 85% in DU-145
cells. We also found that treatment of both control and
PSAP-KD cells with rhPSAP in a dose-dependent man-
ner increased their migratory and invasive behavior (Fig.
2C). However, the overall ability of PSAP-KD cells to
migrate and invade through Matrigel were significantly
less than the control cells indicating a major role for
intracellular PSAP expression in the regulation of cell
migration and invasion.
PSAP down-modulation reduces b1A-integrin expression
Reduction of cell-substrate adhesion in PSAP-KD cells
could be the result of changes in the expression and/or
usage of adhesion receptors such as the intregrin super-
family which exist as a-a n db-subunits. As heterodi-
mers, these subunits could recognize different ECM
proteins. Using RT-PCR and immunoblotting, we
screened control and PSAP-KD clones of PC-3 and DU-
145 cells for a/b-subunit expression. Consistent with
previous reports, using specific primers and antibodies
against integrin-subunits, we were able to detect moder-
ate to high level of expression for a1, a2, a3, a5, a6, aV,
b3,a n db4 integrin subunits [17,18]; no differences
between PSAP-KD and control clones were noted. The
b1-integrin is the most abundant subunit expressed in
PCa cells and tissues; it is capable of forming heterodi-
mers that can bind to FN, LN, and collagen IV [19].
Previous studies showed that PCa cells expressed three
different b1 isoforms: b1A, b1B and b1C,w i t hb1A as the
most abundant isoform [18]. We found that in PSAP-
KD clones only the b1A isoform expression at the pro-
tein level was reduced while b1B or b1C did not change.
Compared to the control clones, the expression level of
both the pre-mature-b1A (105 kDa) and the mature b1A-
isoform (125 kDa) were significantly decreased in PSAP-
KD clones (Fig. 3A). As it was expected, the changes in
the b1A expression pattern were very similar to the total
b1-integrin. Furthermore, to confirm the role of the b1A-
integrin expression in PCa cell adhesion on ECM pro-
teins, we repeated the adhesion assays and used control
clones that were transiently-transfected with a specific
human integrin b1-siRNA oligos. The protein levels of
total integrin b1 as well as b1A isoform were reduced by
80-90% in control clones in both cell lines (Fig. 3B). We
found that, down-modulation of the b1-integrin expres-
sion decreased cell adhesion by 83% for FN and 66% for
LN in PC-3 and by 52% for FN and 69% for LN in DU-
145 (Fig. 3C). These results suggested that reduced
expression of b1A-integrin expression contributed to the
decreased ability of PSAP-KD clones to adhere to base-
ment membrane proteins.
To examine whether changes in protein stability could
be responsible for the reduced b1A expression in PSAP-
KD clones, we investigated the half-life of the b1A pro-
tein by treating a representative clone from both control
and PSAP-KD cells with protein synthesis inhibitor,
cycloheximide (CHX). In agreement with previously
reported data [20], we found that the b1A protein half-
life was approximately 20 h in the control clones, while
it decreased to ~14 h in the PSAP-KD clones in both
cell lines (Fig. 3D &3E). The differences between PSAP-
KD and control clones could be due to the enhanced
degradation rate of the b1A p r o t e i ni nP S A P - K Dw h i c h
allows its earlier disappearance while synthesis of new
proteins are inhibited by CHX.
To understand the posttranslational mechanisms
responsible for the reduced b1A half-life in PSAP-KD
cells, we investigated the involvement of the lysosomal-,
the calpain- and the ubiquitin-mediated proteolysis
pathways. PSAP-KD and control clones were incubated
for different time periods (6t o2 4h )w i t han o n - t o x i c
dosage of leupeptin or NH4Cl (lysosomal protease inhi-
bitors), ALLN (calpain inhibitor), or MG132 (protea-
some inhibitor). Treatment of both the control and
PSAP-KD clones, with leupeptin or NH4Cl, increased
b1A expression in a time-dependent manner beginning
a se a r l ya s6h o u r s( F i g .3 F ) .T h ei n c r e a s ei nt h eb1A-
integrin expression was more evident in PSAP-KD
clones than in the control clones. However, the b1A pro-
tein expression level was not affected by inhibitors of
proteasome or calpain (data not shown). These data
show that down-modulation of PSAP via a lysosomal
proteolysis-dependent pathway increases b1A-integrin
degradation rate. Under our experimental conditions,
cell viability at the end of the treatment period with
CHX or other pharmacological agents was ≥ 95%, as
exhibited by a trypan blue dye exclusion assay.
PSAP down-modulation prevents focal adhesion kinase
activation and focal adhesion complex formation
PSAP-KD cells appeared small and condensed and did
not show morphological evidence of adhesion phenotype
such as spreading, directional membrane protrusion, and
ruffles. These data promoted us to investigate the activ-
ity, expression, or subcellular localization of certain
structural molecules (actin and vinculin), focal adhesion
kinase (FAK) as the most important integrin-regulated
signaling molecule, and adaptor protein (i.e., paxillin)
which are collectively involved in the assembly of focal
adhesion complex. Using whole cell lysates prepared
from subconfluent cells and following their adhesion to
FN or LN, we examined the phosphorylation of FAK at
different tyrosine residues and paxillin by immunopreci-
pitation (IP) of FAK and western blotting with phospho-
specific antibodies. As shown in Fig. 4A, total FAK and
paxillin protein levels were not affected by PSAP down-
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Page 4 of 18Figure 2 The PSAP expression correlated with migratory and invasive potential of prostate cancer cell lines. (A) Transwell filter migration
and invasion assays. Stable PSAP-KD clones of PC-3 and DU-145 were seeded on transwell filters and incubated for 24 h. Basal medium
containing 5% FBS was used as chemo-attractant. For the invasion assay, the membrane was pre-coated with 50 μg Matrigel. (B) Cells migrated
or invaded were counted from ten random fields at 100× magnification using a phase-contrast microscope. (C) Effects of rhPSAP on cell
migration and invasion. A representative control and PSAP-KD clone from each cell line was seeded on transwell filters and incubated for 24 h
(migration) or 48 h (invasion). As a chemo-attractant, basal medium containing 0.5% FBS and various amount of rhPSAP (0, 1, 10, 50 nM) were
included in the lower compartment of the transwell filters. Each bar represented the mean ± SEM of three independent experiments, each in
quadruplicates. ANOVA was used to examine the significance of the data (p < 0.0001) comparing the PSAP-KD clones relative to control clones
in each cell line or among different treatment concentrations for rhPSAP and control.
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Page 5 of 18Figure 3 Effect of PSAP down-modulation on b1A-integrin expression and PCa cell adhesion to FN and LN. (A) PSAP down-modulation
reduces b1-integrin expression. Total RNA was extracted for RT-PCR with primers specific for integrin-b1A,- b1B, and -b1C, and GAPDH. Cell lysates
were analyzed by western blotting with antibodies against b1-integrin and its isoforms b1A, b1B, and b1C and GAPDH. (B) Transient down
modulation of b1-integrin expression. Previously established control stable clones of PC-3 and DU-145 cells were transiently transfected with b1
integrin- or scrambled-siRNA oligos. After 48 h, cell lysates were analyzed for integrin b1 and b1A expression by western blotting. (C) Inhibition of
PCa cell adhesion by transient transfection with integrin b1-siRNA. After siRNA transfection, cells were subjected to adhesion assay on FN- or LN-
coated 96-well plates as described in “Materials and Methods”. (D) b1A-integrin stability. The steady-state b1A protein levels were evaluated by
treating cells with cycloheximide (12.5 μg/ml) for up to 72 h and immunoblotting with anti-b1A antibody. (E) The half-live of b1A-integrin was
evaluated by densitometric analysis of immunoblotting bands using the Quantity One software and the b1A protein levels were calculated as
percentage of non-treatment values after normalization using GAPDH for loading control. (F) Effect of inhibition of lysosomal proteolysis on b1A-
integrin expression. Cells were incubated in the presence or absence of the lysosomal proteolysis inhibitor, NH4Cl (50 mM) for up to 24 h. Cell
lysates were analyzed for b1A protein expression by immunoblotting. The b1A-integrin degradation curve was calculated as described above.
Columns, mean of three independent samples run together; bars, ± SEM, p < 0.0001, Two-sample t-tests with Satterthwaite corrections were
used to compare b1-siRNA versus scrambled siRNA oligos transfected cells following adhesion to FN or LN. ANOVA was used to examine the
significance of the data (p < 0.05) among different cycloheximide treatment periods in PSAP-KD versus control clones. Similar results were
obtained from three independent experiments.
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Page 6 of 18modulation. FAK was constitutively phosphorylated on
tyrosine residues in control transfectants to the levels
similar to PSAP-KD clones. Following 45 or 90 min
adhesion to FN or LN, FAK phosphorylation at Tyr-397,
Tyr-576, Tyr-861, and Tyr-925 and the level of paxillin
phosphorylation at Tyr-118 increased at higher amounts
in the control clones than the PSAP-KD clones (Fig.
4A). To visualize the impairment of cell adhesion in
relation to the changes in b1A-integrin and the assembly
of focal adhesion plaque, we used immunofluoresence
(IF) staining of a representative clone of the control and
PSAP-KD cells. As shown in Fig. 4B, the control cells
spread out on the ECM-coated slides and showed a
strong b1-integrin staining that was mainly localized at
or near the cell membrane region, suggesting a func-
tionally activated b1-integrin. However, the PSAP-KD
cells showed a small and round morphology and a weak
b1-integrin staining which remained non-clustered and
largely in the cytoplasmic region. Furthermore, the con-
trol cells formed several focal contacts as visualized by
phospho-specific antibodies against FAK (Tyr-397) and
paxillin (Tyr-118). The control cells also exhibited a
greater extent of co-localization of FAK and paxillin
proteins. However, the PSAP-KD cells showed clearly
attenuated activation of focal adhesions characterized by
a smaller size and lesse number of focal contacts as well
as irregular localization of FAK and paxillin (Fig. 4B). By
using the antibody against vinculin, another cytoskeletal
protein, similar attenuation in the formation of focal
adhesions was also observed in the PSAP-KD clones
(data not shown).
In addition, stress fibers (F-actin) were also arranged
as long fibers co-localized with vinculin and in parallel
with membrane protrusions in control transfectants. In
contrast, such topological evidence of adhesion pheno-
type was absent in PSAP-KD cells. Overall, these data
suggest that the reduction of b1A-integrin expression
secondary to PSAP-down modulation via the interrup-
tion of the “inside-out” signaling mechanism signifi-
cantly inhibits FAK activity and the proper assembly of
focal adhesion complex and contributes to impaired cell
adhesion and migratory phenotype in PSAP-KD cells.
PSAP down-modulation decreases cathepsin D expression
and proteolytic activity in PCa cells
The multi-step process of invasion phenotype requires
the involvement of matrix-degrading proteolytic
enzymes. Among different classes of proteolytic
enzymes, several lines of evidence demonstrated a
dynamic active physical and functional interaction
between CathD and PSAP [4,6,21]. Therefore, we exam-
ined if down-modulation of PSAP affects CathD expres-
sion and activity. As shown in Fig. 5A, CathD mRNA
expression was not affected by PSAP down-modulation
in any of the cell lines investigated. However, we
observed a significant reduction in the expression levels
of inactive proCathD (~53 KDa), active intermediate
(~48 KDa), and mature (~31 KDa) forms in all PSAP-
KD clones compared to their control counterparts. The
secreted levels of proCathD were also reduced by PSAP
down-modulation. In addition, our analysis showed that
CathD proteolytic activity in the PSAP-KD clones
decreased by 22% in PC-3 cells and by 48% in DU-145
cells (Fig. 5B).
To assess the involvement of CathD in PCa cell inva-
sion, the PC-3 and DU-145 control clones were transi-
ently transfected with human CathD siRNA-oligos. As
shown in Fig. 5C, CathD-siRNA reduced CathD expres-
sion by 90% in both cell lines. Interestingly, knock-down
of CathD expression also decreased the intracellular
expression of PSAP and saposin C (Fig. 5C). In addition,
in vitro migration and invasion assays revealed that
CathD-siRNA decreased cell migration by 76% in PC-3
and by 71% in DU-145, as well as cell invasion by 82%
in PC-3 and 77% in DU-145 (Fig. 5D). Cell viability
assays showed that the decrease of cell migration and
invasion was independent of cell proliferation. Overall,
these data strongly support a close metabolic and func-
tional relationship between PSAP and ProCathD in the
process of migration and invasion in PCa cells.
PSAP down-modulation increases ceramide levels in PCa
cells
PSAP is the precursor of saposins which serve as the
essential co-factors of lysosomal sphingolipid hydrolases.
Therefore, the presence and relative abundance of PSAP
greatly influence the balance between sphingolipid
synthesis and degradation. In the lysosomes, saposins,
derived from PSAP, degrade Cer which physiologically
serves as one of the most important second messenger
systems in the regulation of fundamental biological pro-
cesses such as growth, differentiation, cell adhesion, and
migration as well as the activation of several important
signaling pathways. By using MALDI-mass spectrometry
analysis, we found that a number of cellular Cer with
various hydro-carbon lengths, including Cer-C16, -C18,
and -C24 are accumulated in the PSAP-KD clones.
Total Cer levels in PSAP-KD clones were increased by
46% and 56% in PC-3 and DU-145 cells, respectively
(Fig. 6A). However, we did not observe a significant
change in the levels of sphingosine, a metabolic product
of Cer, as well as glycosphingolipids with short oligosac-
charides, such as lactosyl-Cer and glucosyl-Cer (data not
shown). Next, we examined if Cer can affect b1A-integ-
rin expression in stable control clones of PC-3 and DU-
1 4 5c e l l s( F i g .6 B ) .C 6 - D-e-Cer treatment decreased
both the expression and maturation of b1A-integrin.
Inactive Cer failed to induce any changes in b1A-integrin
expression (data not shown). To determine whether
intracellular Cer accumulation might be responsible for
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Page 7 of 18Figure 4 PSAP down-modulation decreased FAK activity and prevented b1A-integrin clustering and proper assembly of focal adhesion
complex. (A) PSAP down-modulation reduced phosphorylation of FAK and paxillin. Cells were incubated in suspension with gentle rotation for
45 min and then plated onto FN- or LN-coated dishes for 45 or 90 min. Whole cell lysates were extracted and equal amount of proteins were
used for immunoprecipitation with anti-FAK or-paxillin antibody and immunoblotting with phospho-specific antibodies against Tyr-397, -576,
-861, -925 of FAK or Tyr-118 of paxillin. (B) Effect of PSAP down-modulation on b1A-integrin clustering and focal adhesion complex assembly.
Cells were plated onto FN- or LN-coated slides for 2 h, fixed and permeabilized. Immunofluorescence staining was performed with primary
antibodies against integrin b1A, FAK pY397 and paxillin pY118 followed by Cy3 (red) or FITC (green)-conjugated secondary antibodies. F-actin
was stained by Oregon Green 488-phalloidin (green). All images were taken by a Leica DM RA2 fluorescence microscope. Consistent data were
obtained from three independent experiments.
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Page 8 of 18the impairment of cell adhesion to ECM proteins, we
investigated the possible effects of Cer on cell adhesion,
migration and invasion by treating the cells with C6-D-
e-Cer. C6-D-e-Cer in a dose-dependent manner
decreased cell adhesion to FN and LN by ≥ 50% in con-
trol clones from both cell lines (Fig. 6C &6D). It is note-
worthy that the inhibition of cell adhesion on FN and
LN was associated with clear morphological features
such as decreased spreading of the cells and lack of
polarity and membrane protrusions (data not shown)
similar to our observation in Fig. 1D and 4B. In addi-
tion, C6-D-e-Cer, in a dose-dependent manner
decreased cell migration and invasion by 56% and 64%
in control clones of PC-3 cells and by 59% and 66% in
control clones of DU-145 cells, respectively (Fig. 6E
&6F). However, neither the morphological alterations
nor inhibition of cell adhesion, migration, and invasion
were induced by inactive Cer analog C6-L-e-Cer or the
C6-D-t-Cer, the unnatural stereoisomeres of C6-D-e-
Cer, which suggested that these phenotypes are highly
Figure 5 Down-regulation of cathepsin D expression and activity decreased migration and invasion in PSAP-KD cells. (A) PSAP down-
modulation reduced CathD expression and activity. Total RNA was subjected to RT-PCR using specific primers for CathD. Cell lysates and culture
supernatants were prepared from parallel dishes and analyzed by immunoblotting with an anti-CathD monoclonal antibody which recognizes
proCathD (P), intermediate CathD (I), and mature CathD (M). (B) Whole cell extracts were also assayed for CathD enzymatic activity using a kit
with a fluorimetric substrate. The enzymatic activity of CathD was calculated as units/mg total protein. Columns, mean of three independent
samples run together; bars, ± SEM. ANOVA was used to examine the significance of the data (p < 0.0001) comparing PSAP-KD clones versus
control clones. (C) Transient down-modulation of CathD and its effect on PSAP expression. Control clones of PC-3 and DU-145 cell lines were
transiently transfected with specific CathD- or control-siRNA oligos. After 48 h, cell lysates were analyzed for CathD, PSAP, and saposin C
expression by immunoblotting. (D) Migration and invasion assays were performed on parallel-transfected tissue culture plates as described in the
legend to Fig. 2. Columns, mean of three independent samples run together; bars, ± SEM, p < 0.0001, Two-sample t-tests with Satterthwaite
corrections were used to compare CathD-siRNA versus scrambled-siRNA oligos transfected cells. Similar results were obtained from three
independent experiments.
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Page 9 of 18dependent on native Cer configuration. Treatment of
cells with 8 to 32 μMo fC 6 - D-e-Cer or its inactive
enantiomers C6-L-e-Cer and C6-D-t- C e rf o r2 4o r3 6h
followed by a trypan blue exclusion assay showed ≥ 95%
cell viability.
Discussion
We employed an RNA-interference strategy to investi-
gate the molecular events underlying PSAP regulation of
metastatic PCa cell invasion. Stable down-modulation of
PSAP decreased CathD expression and proteolytic activ-
ity, migration, and invasion of the highly invasive and
metastatic PCa cells. In vitro and in vivo studies have
implicated a role for CathD in PCa growth, invasion,
and metastasis [22-25]. Data from transient transfection
studies presented here further support a relationship
between ProCathD and PSAP. The two precursors
PSAP and proCathD are glycoproteins that originate in
the endoplasmic reticulum (ER) which travel together as
a PSAP-proCathD complex and reach the lysosomes by
intracellular trafficking [4,21,26,27]. In endosomal and/
or lysosomal compartments, they undergo mutual pro-
teolytic processing to become the final mature products,
saposins and CathD. PSAP accelerates the activation of
proCathD and stimulates its autocatalytic activity, gener-
ating the enzymatically active intermediate and mature
CathD. In turn, CathD catalyzes the production of sapo-
sins from PSAP [4,27]. In our study, most of the
observed decrease in intracellular CathD was in the
enzymatically active forms (intermediate and mature)
rather than in proCathD levels. This data suggests that
PSAP down-modulation not only affect proCathD con-
version to CathD, but might also influence CathD stabi-
lity and/or synthesis. Taken together our data suggest a
cooperative interaction between PSAP and CathD in
PCa cell migration and invasion.
In PCa cells, b1-integrin is the most abundant and
ubiquitously expressed subunit [19]. Experimental modi-
fications of b1-integrin have been demonstratred to
affect development, cell proliferation, migration, and
activation of downstream FAK-Src signaling [28,29]. We
discovered that, b1A-integrin isoform is not only the
most abundant isoform, but also that down-modulating
cellular PSAP levels significantly reduced its expression
in the highly invasive and metastatic PCa cell lines, PC-
3, DU-145, and C4-2B (data not shown).
Several studies have demonstrated that, upon engage-
ment with ECM components, integrins reorganize to
form focal adhesion complexes, activate FAK autopho-
sphorylation at Tyr-397, and establish a mechanical link-
age with cytoskeletal molecules such as actin and
vinculin, which control cell shape and motility [30].
FAK phosphorylation at Tyr-397 also creates a high-
binding affinity site for Src-homology 2 (SH2) domain
of Src-family kinases and establishes FAK-Src signaling
complex. This association leads to the Src transpho-
sphorylation of FAK within its kinase domain of the
activation loop (Tyr-576) and its C-terminal domain
(Tyr-861 and -925) and to the activation of downstream
adaptor molecules such as paxillin, by phosphorylation
at Tyr-118 [31]. Consistent with the role of integrins in
FAK-Src signaling regulation and downstream activation
of adaptor molecules, we found that decreasing b1A-
integrin expression disrupted these processes in several
ways: a) loss of directional membrane protrusion and
ruffles and clustering of b1-integrin and FAK, b) inability
to form focal adhesion complex, c) decreased Src-bind-
ing to FAK (see additional file 6), d) significant reduc-
tion of phosphorylative activity of FAK at Tyr-397, -576,
-861, and -925, and e) decreased phosphorylation of
paxillin at Tyr-118 in PSAP-KD cells. These data pro-
vide a classical example whereby interruption of integ-
rin-regulated FAK-Src signaling secondary to down-
modulation of PSAP (as a lysosomal protein) leads to a
less adhesive and motile phenotype in PCa cells.
The key findings of this report are the significant
reduction of Src binding to FAK and the lack of proper
assembly of focal adhesion complex in PSAP knock-
down cells. Together, they highlight the importance of
PSAP and saposin C in regulating “inside-out” integrin-
mediated signal transduction pathway(s) leading to
decreased PCa cell migration and invasion. Based on
our data, it appears the observed structural and func-
tional outcomes occur primarily due to reduced b1A-
integrin expression following PSAP down modulation.
In addition, reduction of Src binding to FAK was paral-
leled with decreased Src activity (phosphorylation) in
PSAP-KD cells (data not shown) and did not affect the
activity level of its upstream targets MAPK and PI3K/
Akt (data not shown). As natural cell membrane and
intracellular proteins, PSAP and its active molecular
derivatives, saposin C and its neuro-active domain (pro-
saptide), might also interact with Src alone or in asso-
ciation with focal adhesion complex and other
interactive adaptor proteins (e.g., paxillin) to stabilize
the dynamic state of focal adhesion plaques.
Accumulated Cer levels secondary to PSAP down-
modulation which lead inevitably to reduction of sapo-
sins may be responsible for decreased b1A expression. In
support of this assertion, we found that exogenous Cer
not only decreased PCa cell adhesion, migration, and
invasion, but also reduced b1A-integrin expression in
control clones of PC-3 and DU-145 cell lines. It has
been reported that Cer could inhibit integrin b1-glycosy-
lation and -trafficking to cell surface by disrupting the
function of Golgi complexes [32]. We observed that
PSAP down-modulation induced the accumulation of
cellular Cer without affecting the levels of
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Page 10 of 18Figure 6 Effect of ceramide on PCa cell adhesion, migration, and invasion. (A) PSAP down-modulation increased Cer levels in PSAP-KD
cells. PSAP-KD and control clones of PC-3 and DU-145 cells were subjected to matrix-assisted laser desorption mass spectrometric analysis as
described in “Materials and Methods”. The assay was performed in duplicate and repeated twice independently. Cer content was quantified and
calibrated to the intracellular phosphate (Pi) level and depicted as Cer (pM)/Pi (nM). (B) Effect of Cer on b1A-integrin expression. Control clones of
PC-3 and DU-145 cells were treated with active or inactive Cer analogs or vehicle (DMSO) at the indicated concentrations for 36 h. Cell lysates
were subjected to immunoblotting with specific antibodies against total b1-integrin or b1A-isoform. Inactive Cer analog and DMSO did not affect
integrins expression level. GAPDH antibody was used as control loading. (C and D) Effect of Cer on PCa cell adhesion. Parental PC-3 and DU-145
cells were treated with cell permeable natural Cer analog (C6-D-e-Cer; D-Cer), inactive Cer (C6-L-e-Cer; L-Cer), or vehicle (DMSO) at 1 or 2 μM for
three to five days and then, subjected to cell adhesion on FN- or LN-coated plates as described in the legend to Fig. 1. (E and F) Effect of Cer
on PCa cell migration and invasion. The effect of Cer on migration and invasion of control PC-3 and DU-145 transfectants was examined by
treating cells with active or inactive Cer analogs (described above) followed by migration and invasion assay as explained in the legend to Fig. 2.
Each bar represents the mean ± SEM of three independent experiments. ANOVA models with Dunnett and Tukey corrections were used to
compare cells treated with DMSO, L-Cer, or D-Cer. Statistically significant differences were set at p < 0.05. Consistent data were obtained from
three independent experiments.
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from those other studies of total PASP deficiency in
patients and in experimental mouse models, in which
significant accumulation of Cer as well as lactosyl-Cer
and glucosyl-Cer has been observed [9,10,33]. We spec-
ulate that the balance of Cer metabolism is more sensi-
tive to the relative changes in PSAP expression than is
the metabolism of glycosphingolipids, which essentially
dependes on the presence of a low (threshold) PSAP
level, similar to the residual amount of PSAP in the
PSAP-KD clones, which is comparable to normal pros-
tate epithelial cells (data not shown). It is noteworthy
that the endogenous Cer levels are coordinately regu-
lated by several specialized enzymes and hydrolases
w h i c hp r o d u c eC e ro ru s eC e ra ss u b s t r a t e[ 3 4 ] .E l e -
vated PSAP expression may shift the balance of Cer by
activating certain hydrolases or even by directly regulat-
ing their expression through functional saposins. For
example, saposin D can stimulate the activity of acid
ceramidase, which mediates the conversion of Cer into
sphingosine [35]. This hypothesis is supported by our
finding that ceramidase expression is reduced in PSAP-
KD cells (unpublished data). The Cer level is frequently
decreased in cancer cells and correlates inversely with
the degree of malignant progression [36]. Therefore, it is
conceivable that PSAP overexpression may greatly con-
tributes to Cer-level reduction in invasive and metastatic
cancer cells. Considering the complexity of Cer as a
bioactive sphinogolipid, the underlying mechanisms by
which Cer inhibits PCa cell motility and invasiveness
require further detailed investigation.
Our data indicate a role for soluble PSAP as a para-
crine regulatory factor in migration and invasion. Based
on our study, this paracrine regulatory effect is not suffi-
cient to bypass the intracellular regulatory mechanisms
responsible for significant suppression of migratory and
invasive phenotypes secondary to PSAP down-modula-
t i o n .I ti sl i k e l yt h a tt h er e ceptor-mediated signaling
mechanisms and post-receptor downstream effectors
responsible for the paracrine effect of PSAP may be dif-
ferent from the intracrine regulatory pathways.
Our previous studies also showed that exogenous
saposin C and prosaptide treatment could stimulate PCa
cell growth, involving activating several signaling path-
ways [14]. However, our current data show that under
our experimental conditions, the growth properties of
PCa cells was not affected by either intracellular down-
modulation of PSAP or treatment with rhPSAP.
Furthermore, neither PSAP down-modulation nor
rhPSAP treatment affected the MAPK and PI3K activity
level (unpublished data). Therefore, the observed effect
of exogenous saposin C does not necessarily reflect the
physiological function of extracellularly secreted PSAP
or an intracellular pool of this protein.
PSAP has been demonstrated to be overexpressed in
conditioned media of estrogen receptor (ER)-positive
MCF-7 and ER-negative MDA-MB-231 breast cancer
cell lines as well as in a human SV40-transformed breast
epithelial cells, HBL100 [37]. In MCF-7 conditioned
media, the PSAP expression pattern closely resembled
that of proCathD. Interestingly, the same authors
demonstrated that estrogen (17b-estradiol) increased
secretion of both proteins in a dose-dependent manner.
These observations together with our data support the
hypothesis that the close functional association between
proCathD and PSAP may eliminate tissue barriers by
facilitating proteolytic degradation of basement mem-
brane glycoproteins. PSAP was also identified as a gene
with causative role during functional screening for
tamoxifen-resistance in breast cancer cell line, ZR-75-1
[28]. Further investigation of clinical samples using
qRT-PCR analysis of mRNA levels in 223 ER-positive
primary breast cancers from patients who had recurrent
metastatic disease and were treated with tamoxifen as a
first-line therapy, revealed a high PSAP expression level
for 182 out of 223 patients. In addition, Cox univariate
and multivariate analyses for progression-free survival
correlated the high PSAP expression levels in these
patients with shorter progression-free survival [29].
Independently, using Mass Spectrometry based-proteo-
mic analyses and qRT-PCR for comparative analysis of
non-metastatic primary breast cancer and lymph node
metastases, PSAP was found to be significantly increased
(2 fold) in lymph node metastasis [38]. Similarly, in our
previous studies using punch biopsy samples of meta-
static PCa, genomic amplification of PSAP was detected
in 2 out of 5 lymph node metastases [13]. In addition to
breast cancer and PCa, in a comparative analysis of the
secretomes of an immortalized pancreatic duct normal
epithelial cell (HPDE) and a pancreatic ductal adenocar-
cinoma cell line (Panc1), PSAP expression in Panc1 was
found to 11-fold higher than in the HPDE cell line [39].
Interestingly, PSAP upregulation in Panc1 was asso-
ciated with CathD (6.7-fold) and b1-integrin (3.4-fold)
overexpression. While these reports suggest a role for
PSAP in invasive and metastatic progression of prostate,
breast, and pancreatic tumors, a recent report has sug-
gested that PSAP may inhibit breast and PCa metastasis
by paracrine and endocrine stimulation of thrombos-
pondin-1 expression in a p53-dependent manner in
fibroblasts of primary tumors and distant metastases
[40]. With respect to PCa, the study was based on PC-
3M, a metastatic subline of PC-3 cell line. In addition,
the authors used PC-3M-LN4, a lymph node-metastatic
subline of PC-3M that had been subjected to four cycles
of injection to prostate and harvesting from the lymph
node of athymic nude mice [41]. Due to extensive clonal
selection, it is difficult, if not impossible, to differentiate
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and-effect relationship for the PSAP contribution as an
inhibitor of PCa metastasis. Our analysis of three inde-
pendent PCa progression models based on isogenic cell
lines has revealed a steady-state increase in PSAP
expression levels in invasive and metastatic cells as com-
pared to their parental cells (see additional file 1). These
data show that PSAP expression in PC-3M is at least 3-
fold higher than in its isogenic parental cell line, PC-3,
indicating that, upon metastatic progression, PSAP
expression increases. By analyzing gene microarray
expression data from different sources, the authors also
reported that the relative PSAP mRNA expression in
metastatic PCa was 30% lower than in localized primary
tumors [40]. This analysis is based solely on bioinfor-
matics evaluation which does not necessarily represent
the mRNA and protein expression levels of tumor cells.
As such, a cause-and-effect relationship between PSAP
and the complex multistep process of metastatic pheno-
type in PCa can not be concluded from the study. Clari-
fication of PSAP’s role in invasive and metastatic
progression of PCa and other malignancies requires
additional detailed investigations.
I ns u m m a r y ,w ep r o v i d em e c h a n i s t i ce v i d e n c et h a t
PSAP down-modulation upregulates Cer levels,
decreases b1A-integrin and CathD expression, attenuates
the “inside-out” integrin-signaling pathway, and signifi-
cantly decreases PCa cell adhesion, migration, and inva-
sion. The fact that PSAP is frequently overexpressed in
human malignant cells warrants further investigation of
its role in carcinogenesis and in invasive and metastatic
progression of cancer cells.
Materials and methods
Cell culture
Cell lines used in this study were essentially maintained
as described before [13,14]. Cycloheximide (CHX), leu-
peptin, MG-132, and ALLN were obtained from Sigma
(Saint Louis, MO).
Expression and purification of recombinant human PSAP
in CHO-K1 cells
The full-length cDNA of PSAP gene (GenBank Acces-
sion No. NP002769) was synthesized, tagged at the C-
terminal with hexa-histidine (His6), and subcloned into
the mammalian expression vector pSectag2A (Invitro-
gen, Carlsbad, CA). The pSectag2A vector contained the
Ig leader sequence which allows the secretion of
recombinant proteins. After bacterial transformation,
the sequence accuracy was verified by automated
sequencing in both directions. Stable CHO-K1 clones
expressing high levels of the secreted recombinant
human (rh)-PSAP was obtained using Zeocin as a selec-
tion antibiotic. Recombinant PSAP protein was purified
from culture supernatant using imidazole and Ni-NTA
Superflow Resins (Qiagen, Santa Clara, CA). The mole-
cular size of recombinant PSAP expressed in CHO-K1
cells was similar to that of native PSAP secreted by PC-
3 cells. The size and purity of the purified proteins were
determined by using 4-20% Tris-Glycine gel electro-
phoresis, coomassie blue staining, silver staining, and
western blotting with previously characterized anti-
PSAP antibodies (see additional files 2, 3, 4, 5) [14].
Establishment of stable transfectants of PSAP knock-
down cell lines
Cells were seeded at 2 × 10
5 per well in 6-well plates
overnight and transfected with 2 μg short hairpin (sh)-
RNA plasmid containing a siRNA sequence targeted
against human PSAP or a scrambled control sequence
(SuperArray Biosciences, Germantown, MD) and 5 μl
Lipofectamine 2000 according to the manufacturer’s
instructions (Invitrogen, Carlsbad, CA). After 8 hours of
incubation at 37°C, the transfection medium was
removed and cells were cultured in complete medium
for 48 h. Cells were trypsinized and cultured in the pre-
s e n c eo f1m g / m lG 4 1 8f o rt h es e l e c t i o no fa n t i b i o t i c -
resistant colonies over a period of 2 to 3 weeks. Several
PSAP-knockdown (KD) and -control clones were iso-
lated and analyzed for PSAP expression by western blot-
ting and RT-PCR. We randomly selected two PSAP-KD
clones (P4 and P7 for PC-3 cell line and P15 and P32
for DU-145) and two control clones (C4 and C8 for PC-
3 cell line and C9 and C13 for DU-145 cell line) for
functional studies. The stable cell lines were routinely
examined for PSAP expression and maintained in the
complete medium containing 300 μg/ml of G418.
Transient transfection assays
Cells were seeded in 6-well plates overnight and trans-
fected with 50 pmol of human CathD-, integrin-b1,o r
control-siRNA oligos (Santa Cruz Biotechnology, Santa
Cruz, CA) and 5 μlL i p o f e c t a m i n eR N A i M A Xf o r8h .
The transfected cells were cultured in complete medium
for 16 h and then, in basal medium for additional 24 h
before performing functional assays or harvesting cell
lysates and/or supernatants for protein expression
analyses.
RNA extraction, cDNA synthesis, and semi-quantitative
RT-PCR
RNA was isolated by using the RNeasy Kit according to
the manufacturer’s instructions (Qiagen, Santa Clara, CA).
For cDNAsynthesis, the template (5 μg RNA per sample)
was reverse-transcribed using AffinityScript cDNA Synth-
esis Kit (Stratagene, La Jolla, CA). Semi-quantitative PCR
was performed in total 20 μl volume containing 1 μl
cDNA, 0.2 μMd N T P s ,0 . 4μM primers, and 0.4 μlT a q
DNA polymerase (Promega, Madison, MI). Primers were
synthesized by Integrated DNA Technologies Inc (San
Jose, CA). The oligonucleotides used (according to the
human gene sequences with accession numbers:
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b1C, NM_002778 for PSAP, NM_001909 for CathD, and
NM_002046 for GAPDH, as deposited at the NCBI/gen-
ome data bank) were as follows: b1A,5 ’-AGAATCCA-
GAGTGTCCCACTGG-3’ (sense) and 5’-
TTTCCCTCATACTTC GGATTG-3’ (antisense); b1B,5 ’-
AAGACTTATGTATTAGCTGTCAG-3’ (sense) and 5’-
CCATTGAATAGCTTG CTACAC-3’ (antisense); b1C,5 ’-
TCTGTCGCCCAGCCTGGAGTG-3’ (sense) and 5’-
TTTCCCTCATACTTCGGATTG-3’ (antisense); PSAP,
5’- CCA GAG CTG GAC ATG ACT GA-3’ (sense) and
5’-CAGTTCCCAACAAGGGCTTA-3’ (antisense); CathD,
5’-CTGCACAAGTTCACGTCCAT-3’ (sense) and 5’-
TTCTGCTGCATCAGGTTGTC-3’ (antisense); and
GAPDH, 5’-GGTCGGAGTCAACGGATTTGGTCG-3’
(sense) and 5’-CCTCCGACGCCTGCTTCACCAC-3’
(antisense). After cDNA synthesis, PCR was completed
using a T-gradient model (Biometra, Horsham, PA) under
the following conditions: a denaturation cycle at 95°C for
2 min, 95°C for 45 s, annealing at 58°C for 45 s and elon-
gation at 72°C for 40 s, and a final extension at 72°C for 5
min. The sizes of amplified cDNA fragments and the
number of PCR cycles were: 238 bp/20 cycles for b1A, 278
bp/32 cycles for b1B, 172 bp/32 cycles for b1C, 1000 bp/20
cycles for PSAP, 590 bp/20 cycles for CathD, and 780 bp/
20 cycles for GAPDH. The PCR product was confirmed as
a single band using 1.5% agarose gel electrophoresis. A
non-template control was included in each PCR experi-
ment. Each experiment was repeated three times
independently.
Protein extraction, immunoblotting, and
immunoprecipitation
Cell-free culture supernatants were collected and con-
centrated up to 10 times by using a centrifuge concen-
trator with a 3.0 kDa molecular weight cut-off
membrane (Vivascience, Stonehouse, UK). Protein sam-
ples (2 μg for CathD and 5 μg for PSAP) were subjected
to SDS-PAGE and immunoblotting as previously
described [24]. Normalization of culture supernatants
was based on the total cell number and/or protein con-
tent. Whole cell lysates were also prepared from the
same tissue culture plates and used for immunoblotting
(2 μgf o rC a t h Da n d1 5μgf o rP S A P ) .M e m b r a n e sw e r e
probed with mouse anti-human PSAP (1 μg/ml; Abnova,
Taibei, Taiwan) or mouse anti-human CathD (clone
CTD-19 at 1:2000; Santa Cruz) antibodies and signals
were detected by ECL detection system (GE Healthcare,
London, UK). Direct immunoblotting for cell adhesion
molecules was performed on protein lysates: 1 μgf o r
integrin b1,2 μgf o ri n t e g r i nb1A,2 0μgf o ri n t e g r i nb1B,
30 μg for integrin b1C,a n d5μg for paxillin. We used
the following antibodies for immunoblotting of cell
adhesion molecules: Mouse anti-integrin b1 (Santa Cruz,
clone JB1B at 1:200), rabbit anti-integrin b1A (Millipore,
AB1952P at 1:1000), rabbit anti-integrin b1B and b1C
antibodies provided by Dr. L.R. Languino, University of
Massachusetts (at 1:100), monoclonal anti-paxillin
(Millipore, clone 5H11, 1:1000), and rabbit anti-paxillin-
pY118 (Cell signaling, 1:1000). Anti-GAPDH (Santa
Cruz; 1:4000) was used as control loading.
For immunoprecipitation of cell adhesion molecules,
tissue culture platesw e r ec o a t e dw i t h1 0μg/ml fibro-
nectin (FN, Sigma, Saint Louis, MO) or laminin-1 (LN,
R&D Systems, Minnneapolis, MN) overnight at 4°C and
blocked with 1% BSA/PBS for 1 h at room temperature.
Subconfluent cultured cells were washed with PBS, incu-
bated with Versene (Invitrogen) for 30 min at 37°C and
a final incubation with 0.0025% trypsin for 10 min. The
detached cells were collected by centrifugation and 6 ×
10
6 cells in basal medium and were incubated for 45
min at 37°C with gentle rotation. Equal volume of cell
suspension were either lysed immediately or added to
FN- or LN-coated plates for 45 or 90 min. At the end
of incubation periods, plates were washed with cold PBS
on ice and cells were collected by centrifugation at 300
× g for 3 min. One mg protein lysates were incubated
with 1 μg anti-FAK monoclonal antibody (clone 4.47,
Millipore, Billerica, MA) overnight followed by 2 h incu-
bation with rotation at 4°C in the presence of 20 μl Pro-
tein A/G agarose beads (Santa Cruz). After three washes
with the lysis buffer, the beads were re-suspended in
sample-loading buffer and aliquots of cleared superna-
tant were subjected to SDS-PAGE and immunoblotting
with a mouse anti-FAK (clone 4.47; Millipore) at 1:1000
dilution, anti-FAK-pY397 (MAB1144; Millipore) at 1:250
dilution, rabbit anti-FAK-pY576 (Invitrogen) at 1:1000
dilution, anti-FAK-pY861 (Invitrogen) at 1:1000 dilution,
or rabbit anti-FAK-pY925 (Cell Signaling) at 1:1000
dilution. HRP-conjugated secondary antibodies (Santa
Cruz) were used at 1:1000 dilutions. Where indicated,
subconfluent culture plates were incubated in the basal
medium for 24 h and then, incubated with the protein
synthesis inhibitor, CHX (12.5 μg/ml; Sigma), the lyso-
somal protease inhibitors, leupeptin (100 μM; Sigma) or
NH4Cl (50 mM), the calpain inhibitor ALLN (10 μM;
Sigma), the proteasome inhibitor MG132 (10 μM;
Sigma), or the vehicle alone (DMSO; Sigma) before har-
vesting protein lysates. Immunoblotting bands were
quantified by densitometric analysis using the Quantity
One software (Bio-Rad) and the protein levels were cal-
culated as percentage of non-treated cells with GAPDH
normalization.
Cell proliferation assays
To evaluate the effect of PSAP down-modulation on
cell proliferation, PSAP-KD and control clones were
seeded at 2 × 10
5 in 10 cm tissue culture dishes in
complete medium and incubated for 2, 4, or 6 days. At
the end of incubation period, cells were harvested by
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by trypan blue exclusion assay using a hematocyt-
ometer. To determine the effect of rhPSAP on cell
growth, 2 × 10
3 cells per well were seeded in 96-well
plates in complete medium for 2 days and, after wash-
ing the plates with PBS, cells were incubated in the
presence or absence of rhPSAP at 0.1, 1, 10 nM or
0.5% FBS in basal medium containing 0.1% BSA. After
2 days, the cell number was measured by MTS assay
using CellTiter 96 AQueous One Solution Cell Prolif-
eration/Cytotoxicity Assay Kit according to manufac-
turer’s instructions (Promega). Briefly, 20 μlM T S
solution was added to each well for 2 h incubation and
the absorbance at 490 nm was determined. We used
twelve replicates for each treatment condition.
Cell adhesion assays
To determine the effect of PSAP down-modulation on
adhesion, subconfluent cultured cells were harvested
by versene treatment as described in the immunopreci-
pitation assays for cell adhesion molecules and seeded
at 1.5 × 10
4 cells/well in basal medium on FN- or LN-
coated 96-well plates as described above. After 2 h of
incubation at 37°C, cells were washed twice with PBS,
fixed with 10% formaldehyde, and stained with 0.25%
tolouidine blue each for 15 min at room temperature.
Images were taken at 100× magnification by a video
camera (Nikon DU-S1) fitted to a microscope. The
adhered cells were counted from ten randomly chosen
fields in at least six independent wells. The experiment
was repeated three times independently.
Cell migration and invasion assays
The effect of PSAP down-modulation on cell migration
and invasion was performed using 8-μm transwell fil-
ters (Costar, Corning, NY) with modification as
described previously [14]. For the invasion assay, the
upper compartment was coated with 50 μgM a t r i g e l
(BD Biosciences, San Jose, CA) to form a matrix bar-
rier. A suspension of cells (5 × 10
4 f o rP C - 3o r2×
10
4 for DU-145) in basal medium containing 0.1% BSA
was added to the upper compartment. The lower com-
partment was filled with 400 μl basal medium contain-
ing 5% FBS as chemoattractant. After 48 h for PC-3 or
24 h for DU-145, the non-migratory cells on the upper
s u r f a c ew e r er e m o v e db yac o t t o ns w a ba n dt h ec e l l s
on the lower surface were fixed and stained with the
Diff-Quick solution (Dade Behring, Deerfield, Illinois).
To test the effect of rhPSAP on cell migration and
invasion in stable transfectants, 2 × 10
4 PC-3 or 1 ×
10
4 DU-145 cells were added to each well and incu-
bated 24 h for migration or 48 h for invasion. Basal
medium containing 0.5% FBS in the absence or pre-
sence of rhPSAP at 0.1, 1, 10, or 50 nM was used as
chemoattractant in the lower transwell compartment.
Migrated or invaded cells in each transwell filter were
counted. Imaging and cell counting were performed as
described for cell adhesion assays. The experiment was
performed in quadruplicates and repeated at least
three times independently.
Cathepsin D activity assays
Cells were grown up to 70% confluency in their mainte-
nance medium and serum starved for 24 h. Cells were
collected in extraction buffer containing 10 mM HEPES
pH 7.0, 10 mM KCl, 1.5 mM MgCl2,0 . 5 %C H A P Sa n d
subjected to three freeze-thaw cycles. After centrifuga-
tion at 300 × g for 10 min, the clarified crude cell
extracts were subjected to CathD Assay Kit (Sigma)
based on the hydrolysis by the enzyme of an internally
quenched fluorimetric substrate (i.e., MCA) according
to manufacturer’s instruction.
Immunofluorescence staining and microscopic
analysis
To visualize the effect of PSAP down-modulation on cell
adhesion molecules, subconfluent culture plates were
detached by versene treatment as described for the
immunoprecipitation assays of cell adhesion molecules.
Cell suspensions were incubated in a basal medium for
45 min at 37°C with gentle rotation. Cells were seeded
at 5 × 10
4 per well on FN- or LN-coated slides (Lab
Tek) and incubated for 2 h at 37°C. Immunofluores-
cence staining was preformed as described previously
[42]. Briefly, cells were fixed in 3.7% paraformaldehyde
for 30 min and then, permeablized with 0.3% Triton X-
100 for 15 min. The slides were blocked with 1% BSA
for 30 min, incubated with primary antibodies against
integrin b1 (clone JB1B at 1:50; Santa Cruz), FAK-pY397
(MAB1144 at 1:50 dilution; Millipore), and paxillin-
pY118 (at 1:200, Cell Signaling) overnight at 4°C, and
then with FITC- or Cy3-conjugated secondary antibo-
dies (at 1:200; Jackson ImmunoResearch Laboratories,
West Grove, PA) for 1 h at room temperature. In some
cases, the slides were further stained with Oregon Green
488-phalloidin (at 1:40; Invitrogen) for 30 min. After
optimization of the immunofluoresence staining, each
test was performed in triplicates and repeated three
times independently.
Mass-spectrophotometric analysis of
sphingolipids
Subconfluent culture plates were washed twice with
PBS, and incubated in their basal medium for 24 h.
After washing the plates twice with ice-cold PBS, cells
were scraped, centrifuged, and cellular Cer levels was
measured by matrix-assisted laser desorption mass spec-
trometry (MALDI-MS) which included a panel of C14
Hu et al. Molecular Cancer 2010, 9:30
http://www.molecular-cancer.com/content/9/1/30
Page 15 of 18to C26 Cer species: sphingomyeline, sphingosine, sphin-
gosine-1-phosphate (S-1-P), and the dihydro analogues
of sphingosine and S-1-P. The assay was performed in
duplicate and repeated two times independently. Cer
content was quantitated and calibrated to the intracellu-
lar phosphate (Pi) level and depicted as Cer (pM)/Pi
(nM).
Ceramide treatment
Cell permeable bioactive N-Hexanoyl-D-erythro-sphin-
gosine (C6-D-e-Cer), inactive N-Hexanoly-L-erythro-
sphingosine (C6-L-e-Cer), and N-Hexanoly-D-threo-
sphingosine (C6-D-t-Cer) were purchased from Matreya,
LLC (Pleasant Gap, PA). To determine the effect of Cer
on b1A-integrin expression, cells were treated with active
or inactive Cer analog at 8 to 32 μM for 36 h in com-
plete medium and then, for 24 h in basal medium
before immunoblotting. The effect of Cer on cell adhe-
sion, migration, and invasion was determined by treating
cells with 1 or 2 μM of active or inactive Cer for 5 days
followed by 24 h incubation in basal medium before the
functional assays. The effect of Cer on cell growth was
measured by MTS assay as described in cell prolifera-
tion assay. Cytotoxicity of Cer was determined in paral-
lel experiments using trypan blue exclusion assay.
Statistical analyses
Data were analyzed using SAS v9.1 (SAS Institute, Cary,
NC). Various ANOVA models were used. Nesting of
assayed biological specimens (clones) in treatments were
accounted for, and included as random effects. Post-hoc
comparisons were performed with the Dunnett or
Tukey procedures. Two-sample t-tests with Sat-
terthwaite correction, when needed, were used to com-
pare experimental settings with two groups. Cell counts
were logarithm transformed as necessary before
ANOVA was completed. An experiment-wise signifi-
cance level of 0.05 was used; similarly, simultaneous
confidence intervals of means were obtained.
Additional file 1: PSAP expression in three different prostate cancer
progression models. Cells were cultured in their complete media up to
75% confluency, washed with PBS, and incubated in their respective
basal media for 24 h. Cell extracts and concentrated culture supernatants
were prepared as described in the Materials and methods section. Equal
amount of protein samples (15 μg cell extracts or concentrated culture
supernatants) were resolved by SDS-PAGE under reducing conditions
and subjected to Western analysis using a mouse monoclonal antibody
against human saposin C. The GAPDH antibody was used for protein
loading. Pr. Ep, normal human prostate epithelial cells; C4-2B, a bone
metastatic AI-subline of androgen-sensitive LNCaP; p69, a human normal
prostate epithelial cells immortalized with SV40 T-antigen; M12, a
metastatic subline of p69 cell line; M2182, a highly invasive and
metastatic subline of M12 cell line; PC-3M, a highly metastatic subline of
PC-3 cells.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-4598-9-30-
S1.PDF]
Additional file 2: Expression and purification of rhPSAP in CHO-K1
cells. The cDNA of the human PSAP gene (NM_002778) was tagged with
c-terminal 6×histidine by PCR amplification with the following primers 5’-
AAA GCG GCC CAG CCG GCC GGC CCG GTC CTT GGA CTG-3’ (forward)
and 5’- CCG CTC GAG CTA GTG ATG GTG ATG GTG ATG GTT CCA CAC
ATG GCG TTT GC-3’ (backward). The PCR product was digested with the
restriction enzymes SfiI and XhoI (New England Biolabs) and sub-cloned
into a mammalian expression vector pSectag2A (Invitrogen). The positive
clones were selected and confirmed by DNA sequencing. CHO-K1 (ATCC)
cells were cultured in F12-K medium supplemented with 10% FBS and
1% penicillin-streptomycin. Cells (3 × 10
5) were seeded in 60 mm dishes
and cultured overnight to 20-30% confluency. Cells were transfected
with 4 μg DNA of the pSectag2A/rhPSAP-His6 vector and 20 μl Lipofectin
(Invitrogen) for 16 h. Several stable clones were isolated after selection
with 500 μg/ml of Zeocin for two weeks. One stable clone with the
highest rhPSAP expression was used for large-scale, rhPSAP purification.
The stable cells were cultured in several T500 Triple layer flasks (Nunc) up
to 90% confluency and replaced with 60 ml of OptiMEM medium
(Invitrogen). After 48 h, the culture medium was pooled for
centrifugation at 500 × g for 10 min at 4°C and the cleared supernatant
was filtered with a 0.22 μm membrane. One liter of the supernatant was
mixed with 5 ml Ni-NTA Superflow Resins (Qiagen) and incubated for 4
h at room temperature or overnight at 4°C by slow gyroscopic spin at
100 rpm. The resins were washed with the gradient imidazole at 10, 20,
50, and 100 mM in a binding buffer (50 mM Na2HPO4, pH 8.0, 300 mM
NaCl). The appropriate fractions which contained the purified rhPSAP
protein were pooled, and the buffer was exchanged to PBS by
ultrafiltration using Vivaspin concentrators with a 10 KDa cut-off
membrane. The purified rhPSAP were quantified by measuring OD280/
260 nm; then they were filter-sterilized, and stored at -80°C for future
use.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-4598-9-30-
S2.PDF]
Additional file 3: Coomassie blue staining of the purified rhPSAP
protein. Recombinant proteins expressed in 1 liter of culture
supernatants were purified by using Ni-NTA Superflow resin and
polypropylene purification column. Forty μl of culture supernatant, 20 μl
of imidazole washing, or elution fraction of CHO-K1 stable transfectants
(clone # 2-2) were mixed with a non-reducing sample-loading buffer and
separated in 4-20% Tris-Glycine gel. Solid arrows indicate imidazole-
eluted rhPSAP (~68-72 kDa).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-4598-9-30-
S3.PDF]
Additional file 4: Silver staining and western analysis of purified
rhPSAP. Recombinant PSAP proteins were subjected to SDS-PAGE using
a 10% Tris-Glycine gel. The gels were subjected to silver staining and
western blotting with an anti-PSAP antibody as indicated in the Materials
and Methods section. Both silver staining and immunoblotting showed
the presence of the same molecule with the expected molecular weight
for PSAP.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-4598-9-30-
S4.PDF]
Additional file 5: Biological activity of the purified rhPSAP. The
effect of the rhPSAP protein on prostate stromal cells was determined in
an in vitro migration assay. Briefly, cells were seeded in the upper
compartment of transwell filters in a basal medium supplemented with
0.1% BSA. The lower compartment was filled with 400 μl of either 5%
FBS (as a positive control) or basal media supplemented with 0.1% BSA
with or without rhPSAP at the indicated concentrations. After 24 h of
incubation, the cells were fixed and stained with Diff-Quick. Non-
migrated cells were removed by a cotton swap and the total cell
number per filter was counted. Each sample was assayed in
quadruplicates. Data represented the average of three independent
experiments ± SEM. Statistical significance (p < 0.05) between the control
and treatment groups was evaluated by one-way ANOVA test with
Bonferroni adjustment.
Click here for file
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Additional file 6: PSAP down modulation decreased FAK binding to
Src and Paxillin phosphorylation in metastatic PCa cells. PSAP-KD
cells were incubated in their basal medium for 24 h and whole cell
lysates were extracted and subjected to immunoprecipitation for Src and
immunoblotting with anti-FAK or-paxillin antibody as described in the
Materials and Methods section. Similar data were obtained from three
independent experiments.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-4598-9-30-
S6.PDF]
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